Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2021

May 17, 2021

SELL
$74.73 - $90.69 $388,596 - $471,588
-5,200 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$71.87 - $131.03 $373,724 - $681,356
5,200 New
5,200 $395,000
Q4 2018

Feb 14, 2019

SELL
$80.14 - $106.07 $617,078 - $816,739
-7,700 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$93.92 - $105.72 $272,368 - $306,588
-2,900 Reduced 27.36%
7,700 $747,000
Q2 2018

Aug 14, 2018

BUY
$76.01 - $99.03 $159,621 - $207,963
2,100 Added 24.71%
10,600 $999,000
Q1 2018

May 15, 2018

SELL
$77.67 - $92.63 $427,185 - $509,465
-5,500 Reduced 39.29%
8,500 $689,000
Q3 2017

Nov 14, 2017

BUY
$80.6 - $94.95 $1.13 Million - $1.33 Million
14,000
14,000 $1.3 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $13.1B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Css LLC Portfolio

Follow Css LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

News

Stay updated on Css LLC with notifications on news.